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ABSTRACT
Hoban, Alex Prentice. M. S. The University of Memphis. August 2014. Chitosan
Sponge Microbead Delivery Composite for External Stimuli Responsive Local Drug
Delivery. Major Professor: Dr. Warren Haggard.
Orthopedic wound infections from complex trauma are a prevalent problem.
Systemic delivery of antibiotics may result in sub-inhibitory concentrations of antibiotic
in the wound site due to avascular nature of these injuries and can lead to development of
antibiotic resistant infections. Local antibiotic delivery can overcome this shortcoming of
systemic therapy. A customizable bio-polymer that can be loaded with antibiotics and be
stimulated to release a drug on demand may provide an improved adjunct clinical therapy
for preventing/treating infections in complex trauma injuries. The aim of this study is to
incorporate iron oxide laden chitosan microbeads into the chitosan sponge to create a
local delivery composite that is responsive to externally applied electromagnetic
stimulation. Composites were evaluated for degradation, antibiotic and representative
protein elution, antibiotic activity, and biocompatibility. When excited with ultrasound,
the composite has a higher burst release of a loaded drug followed by less of a sustained
release. Magnetic pulse stimulation increases the release of loaded vancomycin at 3 and
6 hours of elution but seems to decrease the release of loaded amikacin through 48 hours
of elution. Vancomycin and amikacin eluted from the composites was active against
Staphylococcus aureus and Pseudomonas aeruginosa respectively through 48 hours of
elution. These results indicate that the addition of iron oxide containing chitosan
microbeads to the chitosan sponge has potential as a tailorable adjunctive therapy for
infection control.
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PREFACE
The main body of this thesis is a journal article entitled “Preliminary In Vitro
Results for Chitosan Sponge/Microbead Composite for Stimuli Responsive Antibiotic
Delivery.” This manuscript will be submitted to Clinical Orthopedics and Related
Research.
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CHAPTER 1: INTRODUCTION
Statement of Problem
Osteomyelitis, a bone infection caused by bacteria or fungi is a common problem
with complex musculoskeletal trauma in both military and civilian populations [39].
Without proper treatment, these infections can lead to bacteremia which increases the risk
of death [36]. Patients with bacteremia have an increased risk of admission to an
intensive care unit and of in-hospital death [36]. In patients with device related soft
tissue infections, 94% had cases of secondary bacteremia [36]. With the increasing
number of prosthetic joint replacements, infections in these joints are a growing problem
[4]. While the incidence rates of hip and knee replacements are low, approximately 0.51.0% of primary hip replacements, 0.5-2% of primary knee replacements and less than
1% of primary shoulder replacements become infected, their increased use is causing
infections from them to become a major cost to healthcare [4, 18]. These numbers rise
with revisions; there is a 5% infection rate in revision implant replacements and 20% or
more when the revision is because of an infection [18]. There is also increasing evidence
that many revision implant replacements deemed “aseptic” at initial clinical assessment
are in fact infected [37]. The mortality due to hip replacement infections can be as high
as 10% [4]. Open bone fractures also carry a high risk of infection at 10-50% [60]. A
retrospective study has shown that all open type III fractures among combat casualties
were contaminated with bacteria [26]. Among these patients, 37% experienced delayed
union and 14% resulted in amputation [26].
Wound infections are also becoming harder to treat with the occurrence of
antibiotic resistant bacteria. The most common antibiotic resistant bacteria is Methicillin-
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Resistant Staphylococcus aureus (MRSA), but many other antibiotic resistant bacteria
species are becoming more prevalent such as vancomycin resistant enterococci [36]. The
presence of MRSA in wound and bone infections makes them increasingly harder to treat
and abate because of limited choices of antibiotic [4]. According to the Center for
Disease Control and Prevention (CDC), 18,650 patients died in hospitals from MRSA
infections in 2005 [28].
Systemic delivery of antibiotics is not always the most effective delivery method
for treating infected injury/implant sites due to avascular areas in the body, such as
around an implant or with complex trauma [21]. This often times results in subtherapeutic concentrations of antibiotic at the infection site [7, 9, 22, 40]. Systemic
antibiotic delivery can also have toxic side effects [7, 9, 21, 22, 40]. Many times
systemic delivered antibiotics can be ineffective and result in antibiotic resistant
infections due to relatively low antibiotic concentrations at the infection site. To
overcome limitations of systemic delivery in these cases, antibiotic therapy using
localized delivery systems may be used [21]. Local drug delivery and in particular, local
delivery that can be controlled from external stimuli (stimuli responsive) and tailored to
the patient, would be more effective because it can overcome the shortcomings of
systemic antibiotic therapy through sustained local delivery of antibiotics.
Many individual bacteria that are partially resistant to systemic antibiotic therapy
are much more susceptible to the higher levels of localized antibiotic delivery [21].
Another advantage of localized antibiotic delivery is that the antibiotic can reach the
infection site much more quickly than systemic delivery [21]. Stimuli responsive
delivery systems offer more control over the release profile of the antibiotic, or other
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drug, and are thus better treatment options over systemic antibiotic delivery [54]. Thus
local, stimuli responsive drug delivery presents improved options for treating and
preventing all types of wound infections [21].
Treatment of bone infections mainly involves operative debridement, removal of
all foreign bodies and antibiotic therapy [39]. Intravenous antibiotics are usually
prescribed for 3 weeks then oral antibiotics are prescribed for 3 weeks [39]. According to
the East Practice Management Guidelines for prophylactic antibiotic use in open
fractures, further debridement of the wound after 24-48 hours may be necessary if
infection is still present [43].
Background
There are currently many different localized drug delivery vehicles for
treating/preventing infections. Each localized delivery vehicle has its own advantages
and disadvantages in their applications.
One delivery vehicle is calcium sulfate. Calcium sulfate acts as an
osteoconductive scaffold, because of the calcium, and does not need to be removed after
implantation because it is biodegradable [10, 41, 51, 53]. In some cases, calcium sulfate
has been shown to promote bone growth and the healing of bone defects [41]. The
calcium sulfate pellet is reabsorbed in human tissue in 4 to 6 weeks without stimulating
an anti-inflammatory response [53]. Nelson et al found that bactericidal concentrations
of tobramycin, 11868 µg/ml on day 1 and 2.5 µg/ml on day 7, could be released by
calcium sulfate pellets [41]. As of 2005, Wright Medical Technologies makes a
commercially available kit allowing antibiotic loading of already sterilized calcium
sulfate powder for the treatment of bone defects [19, 51]. This calcium kit can be used
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with tobramycin or vancomyin and result in calcium sulfate pellets that are 4.25% and
3.64% by weight of antibiotics respectfully [19]. Coripharm, of Dieburg, Germany, also
makes a carrier material out of calcium sulfate and nanocrystalline hydroxyapatite that
can be used to carry therapeutic agents [51]. However, calcium sulfate has some
disadvantages as a local delivery vehicle. Some studies have shown that there is a shortterm effect of suspected rapid dissolution that can lead to inflammatory reactions within
the implant site and drainage problems from the wound [11, 32, 51].
Another local antibiotic delivery vehicle is polylactide (PLA)/polylactide-coglycolide (PLGA) and polyglycolic acid (PGA). PLA is a thermoplastic, amorphous
polymer that is very widely used as a vehicle for local delivery of drugs [35]. PLA and
PGA are both biodegradable and biocompatible [34, 35]. Poly (L-lactic acid) (PLLA) is
widely used in the biomedical field [34]. PLLA is used in surgical sutures, implants for
bone fixation, drug delivery devices, and materials for tissue engineering [34]. However,
PLA and PGA have some drawbacks as local delivery vehicles. Nanoparticles
formulated using PLA and PGA have a rapid uptake by the reticuloendothelial system
[15]. These particles show a low drug loading efficiency, inability to encapsulate a wide
range of drugs particularly hydrophilic drugs, and an inability to release their drug
payload completely [13, 15]. In addition to these drawbacks, PLA and PGA degrade into
various forms of lactic and glycolic acids [34, 35, 51]. Lactic acid is naturally occurring ,
but the high concentration of acid, both lactic and glycolic, that PLA and PGA creates
upon degradation lowers the pH of the surrounding environment which can cause
inflammatory reactions [10, 51].
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Collagen is another polymer used as a drug delivery system. Collagen is a major
component of the extra cellular matrix (ECM) which makes collagen biocompatible,
biodegradable, and useful in designing drug delivery systems [29]. Conventional
collagen gels containing a drug lead to burst release of the drug [17, 29, 62]. In addition,
collagen gels exhibit good cell and tissue compatibility [62]. The two most readily
available forms of injectable collagen gels are suspensions of collagen fibers and nonfibrillar, viscous solutions of collagen [62]. The issue with collagen mixtures in gels or
sponges is that the collagen network is much too porous to retain many active agents such
as antibiotis or biologically active agents. The drugs are released too quickly in a burst
effect, rather than sustained, possibly leading to cytotoxic concentrations of antibiotics
and/or resistant antibiotic strains [62]. To improve the drug release profile, secondary
mechanisms of retention, such as the addition of other solid materials or crosslinking,
have to be employed into the collagen sponge or gel which add complexity and decrease
the ease of use [62]. Another drawback is that the randomly oriented gels are too weak
for surgical manipulation or to bear tensile loads in vivo [62, 64]. These drawbacks make
collagen a less than ideal drug delivery system.
Polymethymetacrylate (PMMA) is another local antibiotic, non-degradable drug
delivery vehicle. PMMA beads loaded with antibiotics have been used for many years in
orthopedic surgery [51]. PMMA with added antibiotics has also been used to lower the
infection rates of total hip arthroplasty [53]. PMMA is considered to be the gold standard
in long-term local delivery of antibiotics [42]. However, PMMA is not ideal. The
manufacturing of the PMMA beads involves a significant exothermic reaction [53]. This
heat production can be problematic because many antibiotics are heat sensitive and may
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be compromised by the manufacturing process [53]. Also, PMMA is a dense acrylic
polymer and does not degrade meaning not all the loaded antibiotics are available for
local release [53]. This lack of degradation means that PMMA beads with antibiotics
implanted during surgery will require an additional surgery for their removal [53]. While
the PMMA beads are implanted, a fibrouslayer begins to form around the beads which
can serve as a nidus for infection even with the antibiotics in the beads [53]. Once the
PMMA beads have been removed, they can leave behind dead space which can also be a
nidus for infection [53].
The drawbacks of all of these delivery systems have led to a search for a better
local delivery method. A more biocompatible, degradable, tailorable polymer is
preferred for a more controllable local drug delivery vehicle. Chitosan, a biopolymer, is
a promising local drug delivery biomaterial.
During the past 20 years, a substantial amount of work has been reported on the
polymer chitosan and its potential use in various bioapplications [12]. Chitosan is
appealing because it is made from an abundant renewable resource, chitin, and is a
compatible and effective biomaterial that can be used in many applications [12, 27, 30,
50, 67]. The chitosan molecule is a copolymer composed of N-acetyl-D-glucosamine and
D-glucosamine units available in different grades depending upon the degree of
acetylated moieties [12]. The main commercial sources of chitosan are the shell waste of
shrimp, lobster, krill, and crab [12, 50]. Depending on the source and preparation
procedure, chitosan‟s molecular weight may range from 300 to over 1000 KD with a
degree of deacetylation (DDA) from 30% to 95% [12, 27, 50].
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The excellent biological properties of chitosan make it a great biomaterial for
drug delivery systems [12]. It has attracted attention as an excellent mucoadhesive in its
swollen state and natural bioadhesive polymer that can adhere to both hard and soft
tissues [12]. A number of colloidal delivery systems based on chitosan have been
presented for the mucosal delivery of polar drugs, peptides, proteins, vaccines and DNA
[12]. Clinical tests carried out using chitosan-based biomaterials do not report any
inflammatory or allergic reactions following implantation, injection, topical application,
or ingestion in the human body [12]. Chitosan films with low degree of deacetilation
(DDA) have proven to be good biomaterials for wound healing because they adhere to
fibroblasts and favor the proliferation of keratinocytes, thereby assisting epidermal
regeneration [12]. Chitosan is biodegraded in the human body primarily by lysozyme
[12]. Chitosan is considered to be a non-toxic, biologically compatible polymer that has
been approved for dietary applications in Japan, Italy, and Finland as well as being
approved by the FDA for use in wound dressings [12]. Chitosan has also shown
antimicrobial, hypocholesterolemic, haemostatic, fungistatic, immunity-enhancing and
antitumor effects, drug delivery, and accelerating calcium and ferrum absorption
properties [12, 27, 30, 67]. The US military has used a chitosan patch to control bleeding
in wounds sustained by soldiers in Iraq and Afghanistan [42].
An application of the chitosan films as a local adjunctive therapy for traumatic
wounds was shown by Noel et al. with in vitro studies. Noel et al. showed that chitosan
films delivering daptomycin can inhibit S. aureus [42]. The only drawback is that the
chitosan film shows extremely high initial release with a much smaller release profile at
the 72 hr time point where a second surgical debridement may be necessary in the
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infection treatment [42]. The chitosan film has been shown to elute antibiotic much more
rapidly than antibiotic loaded PMMA, the gold standard in long-term antibiotic release,
without the need for retrieval surgery [42]. One method to help obtain a more sustained
release profile of the film was to crosslink the chitosan [55]. However, the processing of
crosslinking agent is not a simple one. Many different crosslinking agents, such as
glutaraldehyde, crosslink chitosan very well but are not biocompatible and in some cases
are toxic [42, 55]. Genipin has been shown as a potential crosslinking agent for chitosan
with lower toxicity than glutaraldehyde [38]. She et al. also found that when they
crosslinked chitosan with citrate, they could make a pH sensitive chitosan film [55].
They showed that this film would release more drug as the pH decreased [55]. This pH
sensitivity of chitosan films and other constructs offers the potential for a more
controllable release profile.
Chitosan sponges are another local drug delivery vehicle that has numerous
applications. Sponges are soft and flexible materials with a well interconnected
micropore structure [24]. Chitosan sponges retain a moist atmosphere, high swelling
capacity, and wound healing without scar formation [24]. Chitosan sponges are a
degradable antibiotic delivery system that can be loaded immediately before implantation
as an adjunctive therapy [43]. Oungbho et al. was able to produce pH responsive drug
delivery using chitosan sponges [45]. This was achieved because chitosan is soluble at
low pH [45]. Oungbho had a faster release of drug from chitosan sponges in low pH
media (acidic) compared to sponges in neutral pH media [45]. Also, Noel et al. found
that amikacin and vancomycin could be loaded into an already fabricated chitosan sponge
and provide a sustained release out to 72 hours possibly preventing a second surgical
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debridement [43]. This study by Noel shows that the chitosan sponge delivery system
can sustain very high release levels of antibiotics needed for early stage infection
prevention [43].
Chitosan microspheres are another chitosan based local drug delivery vehicle.
The use of microsphere-based therapy allows drug release to be carefully tailored to the
specific treatment site through the choice and formulation of various drug-polymer
combinations [56]. Using innovative microencapsulation technologies, and by varying
the copolymer ratio and molecular weight of the polymer, microspheres can be developed
into an optimal drug delivery system which will provide the desired release profile [56].
Chitosan microspheres are used to provide controlled release of many drugs and to
improve bioavailability of degradable substances such as protein or enhance the uptake of
hydrophilic substances across epithelial layers [56]. The crosslinking agent
tripolyphosphate (TPP) has been shown to increase the sustained release of ampicillin
from chitosan microspheres [3]. Different crosslinking agents have been used showing
promising release profiles for many different drugs [1, 3, 16, 25, 48, 49, 56, 63, 68].
Jiang et al. was able to incorporate iron oxide (Fe3O4) nanoparticles to make magnetic
chitosan microspheres [25]. This particular advancement is of extreme importance
because with these nanoparticles, a more controlled, stimuli responsive drug delivery
might be achieved.
Chitosan, in conjunction with other materials, may offer the ability to control drug
dosing in terms of quantity, location, and time; improved control helps in maximizing the
therapeutic effect while minimizing side effects [5]. Many different stimuli such as
temperature, pH, ultrasound, and enzymatic action have been proposed as different
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triggering systems [5]. Nanoparticles were first developed around 1970 and are defined
as solid colloidal particles, less than 0.1 µm in size, that consist of macromolecular
compounds [31]. Nano sized iron oxide (Fe3O4) particulates have emerged as versatile
materials for different applications due to their magnetic, electronic, photonic and optical
properties [8]. The addition of iron oxide nanoparticles offers the ability for greater
control of the drug release profile. In particular, these molecules produce heat when in
the presence of an alternating magnetic field [33]. Ultrasound or sonication, can also
trigger a heating effect in these particles [5]. This heating effect which changes the
polymer chain arrangement could be used to control the release of a drug from a drug
delivery system. Iron oxide nanoparticles have the potential to be successfully used in
many different stimuli responsive drug delivery systems [8, 31].
One major drawback of chitosan is that high DDA chitosan has low solubility in
aqueous solvents, which limits manufacturing processes and degradation [65]. One way
to improve this low solubility is with pulsed electric fields (PEF) [65]. The technology of
PEFs has been widely used for non-thermal pasteurization, enhancing chemical reactions,
and modifying large molecules [65]. PEFs have also been used to treat cancer and
permeabilize organelles for drug delivery [44]. The PEF causes the release of calcium
from the endoplasmic reticulum and can initiate apoptosis [44, 61, 66]. W. Luo et al.
found that stimulating chitosan with PEFs would significantly deform chitosan,
decreasing the molecular weight, and significantly damaging the crystalline region of
chitosan [65]. This deformation of chitosan offers new ways to help control the
degradation rates of chitosan.
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Hypothesis
We hypothesize that a smart stimuli-responsive biomaterial local delivery system,
with magnetic nano-particles (MNP) impregnated in chitosan microbeads all contained
within a chitosan sponge, will result in enhanced, tunable local delivery composite for
infections in-bone defects. The hypothesis and objectives we developed are based on the
review of past local drug studies, our own research, and the research of others.
Objectives
1. Demonstrate that the chitosan sponge-microbead composite will release
antibiotic(s) upon stimulation by alternating magnetic field or sonication.
2. Determine the delivery systems antibiotic(s) elution profile over 72 hours and
compare results to sponges loaded with the same antibiotic.
3. Determine the delivery system‟s degradation and cytocompatibility.
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CHAPTER 2: PRELIMINAY IN VITRO RESULSTS FOR CHITOSAN
SPONGE/MICROBEAD COMPOSITE FOR STIMULI RESPONSIVE
ANTIBIOTIC DELIVERY
Introduction
Osteomyelitis is a common problem caused by complex musculoskeletal trauma
[39]. Without proper treatment, it can lead to bacteremia, which increases risk of
admission to an intensive care unit and death [36]. One cause of bacteremia is medical
device related soft tissue infections [36]. With joint replacements and revisions
increasing, infections leading to bacteremia in these joints are also on the rise [4].
Currently, a 2% or less infection rate can be found in primary joint replacements, 5%
infection rate in revisions and 20% or more when the revision is because of an initial
infection [18]. Open bone fractures also carry an extremely high risk of infection at 1050% [60].
Wound infections are also becoming much more difficult to treat because of
increased antibiotic resistance in bacteria. Systemic delivery of antibiotics is not always
effective and often do not achieve high antibiotic concentrations [7, 9, 22, 40]. Systemic
antibiotic delivery can also have toxic side effects and can result in antibiotic resistant
infections [7, 9, 21, 22, 40]. Due to systemic antibiotic therapy relying on vascularity to
spread, avascular areas of the body cannot be reached [21].
Stimuli responsive local drug delivery presents more controlled options for
treating and preventing wound infections [21]. Bacteria that are resistant to systemic
antibiotic therapy are more susceptible to higher levels of localized antibiotic delivery
and the potential timing of dosage release can be controlled [21]. Another advantage is
the antibiotic can reach the infection site more quickly than systemic delivery and offers
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more control over the complete release profile [21, 54]. If an external stimuli can
stimulate the release of antibiotics, this offers more control over the antibiotic release
profile than just local delivery [5, 8, 31, 33].
There are many different localized drug delivery vehicles for treating infections;
however, the drawbacks of these delivery systems have led to a search for a better local
delivery method [10, 11, 13, 15, 32, 34, 35, 51, 53, 62, 64]. Chitosan is appealing
because it is made from an abundant renewable resource, chitin, and is a compatible,
biodegradable, effective, and non-toxic biomaterial with many applications [12, 27, 30,
50, 67]. Chitosan has been approved for dietary applications in Japan, Italy, and Finland
and by the FDA for use in wound dressings [12]. Chitosan sponges can be loaded
immediately before implantation as an adjunctive therapy [43]. Also, Noel et al. found
that amikacin and vancomycin could be loaded at point of care into an already fabricated
chitosan sponge and provide a sustained release out to 72 hours as adjunctive therapy for
trauma care [43]. This study by Noel shows that the chitosan sponge delivery system can
sustain very high release levels of antibiotics needed for early stage infection prevention
[43].
Our preliminary study investigated a chitosan sponge and microbead composite
that will have the capability of releasing antibiotics upon stimulation by a pulsed
magnetic field due to the addition of iron oxide nanoparticles, Fe3O4, to the chitosan
microbeads. The chitosan microbeads with iron oxide nanoparticles, these nanoparticles
produce heat in presence of pulsed magnetic fields (PMFs), will be “suspended” inside
the sponge and are stimuli responsive. Upon stimulation by pulsed magnetic field, the
chitosan microbead was modified from heat produced by nanoparticles and release
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antibiotics According to the East Practice Management Guidelines for prophylactic
antibiotic use in open fractures, a „„second-look‟‟ at a wound may be performed at 24-48
hours with subsequent debridement necessary [23]. Ideally, our composite will remove
the need for the subsequent debridement.
Based on the needed improvements of infection treatment in orthopedic
infections, we asked the following questions: Can we fabricate an adaptable,
cytocompatible and biodegradable chitosan sponge/microbead composite capable of
absorbing antibiotics, or a representative bone related protein, and eluting them in
response to either ultrasound or pulsed magnetic field as an adjunct therapy to
debridement and lavage? Are these composites capable of releasing levels of antibiotic to
inhibit the growth of Pseudomonas aeruginosa and Staphylococcus aureus, two
representative bacteria known to infect orthodpedic infections [43]?
Materials and Methods
We investigated the ability of a chitosan sponge and microbead system to deliver
antibiotics upon outside stimulation over 72 hours. Our composite is made up of a
chitosan sponge, hydrated with chitosan microspheres that are 50% w/w Fe3O4
nanoparticles. According to the East Practice Management Guidelines for prophylactic
antibiotic use in open fractures, a „„second-look‟‟ at a wound may be performed at 24-48
hours with subsequent debridement necessary [23]. Because of this “second-look”
between 24-48 hours, our selected elution time points are 1, 3, 6, 24, 48, and 72 hours.
The Fe3O4 nanoparticles were made following the methods of Hu et. al[20]. 1.35g
of FeCl3·6H2O was dissolved in 40 ml of ethylene glycol to form a clear solution. Then
1.0g of polyethylene glycol 20000 and 3.6g of NaAc·3H2O were added to the solution.
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Once the reactants were fully dissolved, the solution was transferred into a Teflon-lined
autoclave vessel with a capacity of 50ml, and heated at 200oC for 8 hours. After the
autoclave, the products were collected, rinsed with de-ionized water and ethanol several
times, then dried in a vacuum oven at 60oC for 6 hours.
Chitosan (83% DDA, MW=250kDa) is obtained from Chitinor AS (Norway).
Chitosan microspheres containing Fe3O4 nanoparticles were made following the
procedures in Jain et. al[57]. A 4% w/v solution of chitosan, 5% w/v aqueous acetic acid,
2% w/v Fe3O4 nanoparticles, 5mg/ml antibiotic (either amikacin or vancomycin both
from MP Biomedicals) was prepared. This solution is dispersed in a 1:1 mixture of light
and heavy mineral oil (paraffin oil from Fisher Chemical) containing .013 w/v Span 80
surfactant (Sigma Life Science). This oil solution was allowed to mix for approximately
15 minutes. Next, genipin (Wako) was added to make the solution 5mM of genipin. The
solution was then stirred overnight (approximately 20 hours) allowing the genipin to
crosslink the chitosan. After crosslinking, the solution was rinsed with solutions of
hexanes, methanol, and acetone, separately in this sequence to remove the mineral oil,
and then allowed to air dry in laboratory chemical fume hood.
Chitosan sponges were made following the procedure in Noel et. al[43]. 10.0
grams of Chitofarm S (83% DDA, 250550 Da) chitosan was dissolved in 1% v/v blended
acid solvent (75/25 lactic to acetic acid). This solution was allowed to stir for between 14 hours or until the chitosan was dissolved. Then 35ml of the chitosan solution was
pipetted into small aluminum weigh dishes. These dishes were frozen at -80oC (Thermo
Scientific Forma 900 Series -80oC freezer) for at least one hour, then placed into a freeze
dryer (Labconco Freezone 2.5) and lyophilized for 48 hours. The chitosan solution in the
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dishes formed sponge-like components during the lyophilization. These sponges were
neutralized in 0.6 M NaOH for 30-40 seconds, and then rinsed with distilled water until a
the rinsing solution read neutral (pH of 7) on a pH strip. The sponges were again frozen
at -80oC and lyophilized a second time for 48 hours. The chitosan microspheres
containing amikacin and Fe3O4 nanoparticles were hydrated into the sponges after the
second lyophilization with either distilled water or a solution of 5mg/ml antibiotic. Preloaded composites were lyophilized a 3rd time where as point of care composites went
straight into elution testing.
The groups tested are represented in Table 1. Each elution was performed in 20
ml of PBS. Three 1 ml samples were taken from each composite (n=3) at every time
point: 1, 3, 6, 24, 48, and 72 hours. At each time point, PBS was completely refreshed.
Samples were frozen until they were analyzed. For the magnetic pulse, a 17 turn coil
given 27.8 volts and 12.9 amps with a maximum Vp-p of 1200 volts and producing a field
pulsed at 109.7 kHz was used. The magnetic pulse represents a more clinically viable
stimulation method than sonication so samples were stimulated for 5 min in between each
time point. The amikacin levels were measures using an Abbott TDx FLx Immunology
Analyzer. Vancomycin levels were measured using a protein assay (Pierce BCA Protein
Assay Kit) or high pressure liquid chromatography (HPLC). Statistical analysis of the
concentrations was performed using the Students T-Test.
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Table 1. Elution groups for amikacin and vancomycin release due to magnetic pulse
(MP).
Sponge
Stimulated
Sponge
Sponge loaded
Sponge
loaded with
with magnet
Composite
loaded
with beads
loaded with
beads loaded pulse for 5 min
Group
with
loaded with
vancomycin
with
in between
amikacin
amikacin
vancomycin each time point
MP 1
Yes
No
No
Yes
No
MP 2
Yes
No
No
Yes
Yes
MP 3
No
Yes
Yes
No
No
MP 4
No
Yes
Yes
No
Yes

The biological activity of the sponge eluates were analyzed using turbidity assays.
Samples were tested to determine if antibiotic is still active against P. aeruginosa (PA
ATCC 27317, minimum inhibitory concentration (MIC) 6.25-12.5 µg/ml amikacin) or S.
aureus (UAMS 1 MIC 1.56-3.125 µg/ml vancomycin) depending on whether amikacin or
vancomycin were eluted, respectfully [43]. Tubes were prepared with trypticase soy
broth (TSB) and inoculated with respected bacteria [43]. Positive and negative controls
were used. The sample eluates were added to the tubes, resulting in a 10x dilution, and
incubated at 37oC for 24 hours [43]. After incubation, the samples were shaken and read
with a spectrophotometer at 530 nm [43].
A protocol modified from ASTM F813-07 “Standard Practice for Direct Contact
Cell Culture Evaluation of Materials for Medical Devices” was followed in order to
assess the direct contact biocompatibility of the sponge/microbead composite. Normal
human dermal fibroblasts (NHDFs) were seeded at 3.66×104 cells/ml or 1.43×105
cells/ml and allowed to grow to near confluence on 12 well polystryrene tissure culture
plates in Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and penicillin (100 units/ml), streptomycin (100 mg/ml), and
amphotericin B (0.25 µg/ml) for either the 1 or 3 day treatments, respectively. Chitosan
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sponge/microbead composites as well as control polyurethane sponges were soaked in
pre-warmed sterile 1 x PBS for approximately 20 minutes. Single 8mm diameter sponges
(n=3) were gently placed in each well in direct contact with the cell monolayer. Cells
were incubated for either 1 or 3 days when biocompatibility was assessed with Cell TiterGlo® Luminescent Cell Viability assay which measures ATP production.
Degradation of the chitosan sponge/microbead composite was determined by first
recording the mass of each composite sample, placing specimen in 15 containers (one
sample per container) containing PBS solution supplemented with 1 gm/ml of lysozyme
(MP Biomedicals). Then at 2, 4, 6, 8, and 10 days the composites replicate specimen of
each composite (n=3) were removed from lysozyme solution dried in a vacuum over at
60oC-80oC for two days and finally re-weighed. Every two day, during the 10 day test
period, the lysozyme solution was removed and replaced from each sample container.
The percent degradation was determined from the difference in weights of each
composite (

𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔 𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔 𝑡
𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔 𝑡

). This is a destructive test so 15 composites were

used (3 for each time point).
Results
This study attempted to fabricate an adaptable, cytocompatible and biodegradable
chitosan sponge/microbead composite capable of absorbing antibiotics and eluting them
in response to pulsed magnetic field as an adjunct therapy to debridement and lavage.
The point of care loaded sponge/microbead composite initially has a burst release (at 1
hour) followed by a sustained release (through 72 hours) of antibiotics without
stimulation. The magnetic pulse elution results are shown in Figures 1a, 1b, 1c, and 1d.
When magnetic pulse stimulus is applied to the composites loaded with amikacin and
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vancomycin, the release levels of amikacin are decreased at 3 (655 µg/ml), 6 (191.2
µg/ml), 24 (89.4 µg/ml), and 48 hours (41.8 µg/ml) compared to non-stimulated
composites. However, when magnetic pulse is applied, the levels of vancomycin
released are increased at 3 (319.4 µg/ml), 6 (150.3 µg/ml), and 72 hours (47.6 µg/ml)
compared to non-stimulated composites. The degradation profile of the composite is
shown in Figure 2. The composites which are primarily chitosan sponge, degraded to
approximately 90% weight remaining after 10 days. The cytocompatibility results are
shown in Figure 3. The composites reduced cytocompatibility after 1 day (94%) and 3
days (92%) when compared to control polyurethane sponge. The cells from both the
polyurethane sponges and composites had similar appearances.
Can these sponge/microbead composites release inhibitory levels of antibiotics to
inhibit the growth of Pseudomonas aeruginosa (PA) and Staphylococcus aureus? The
point of care loaded magnetic pulse activity results are presented in Table 2. The
amikacin loaded composites (MP 3 and MP 4 from Table 1) eluted inhibitory levels of
amikacin against PA for 48 hours and eluted inhibitory levels of amikacin and
vancomycin against S. aureus for 24 hours. The vancomycin loaded composites (MP 1
and MP 2 from Table 3) eluted inhibitory levels of vancomycin against S. aureus for 48
hours.
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Figure 1a: Amikacin elution profile in response to magnetic pulse stimulus. Groups are
denoted in Table 3. Error bars denote standard deviation. * denotes statistical difference
(T-test <0.05) from non-stimulated composite (MP 1). Amikacin was pre-loaded into the
microbead portion of the composite causing much lower elution levels.

Figure 1b: Amikacin elution profile in response to magnetic pulse stimulus. Groups are
denoted in Table 3. Error bars denote standard deviation. * denotes statistical difference
(T-test <0.05) from non-stimulated composite (MP 3). Amikacin was point of care
loaded into the composites causing higher release levels.
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Figure 1c: Vancomycin elution profile in response to magnetic pulse stimulus. Groups
are denoted in Table 3. Error bars denote standard deviation. * denotes statistical
difference (T-test <0.05) from non-stimulated composite (MP 1). Vancomycin was point
of care loaded into the composites causing higher release levels.

Figure 1d: Vancomycin elution profile in response to magnetic pulse stimulus. Groups
are denoted in Table 3. Error bars denote standard deviation. * denotes statistical
difference (T-test <0.05) from non-stimulated composites (MP 3). Vancomycin was preloaded into the microbead portion of the composites causing lower release levels.
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Table 2: Activity of composite groups against either PA or S. aureus. Groups are
denoted in Table 3. + denotes bacterial growth. – denotes inhibition of growth.
Composite
Hr 1
Hr 3
Hr 6
Hr 24
Hr 48
Hr 72
Group
PA/Staph PA/Staph PA/Staph PA/Staph PA/Staph PA/Staph
MP 1
MP 2
MP 3
MP 4

+/+/-/-/-

+/+/-/-/-

+/+/-/-/-

+/+/-/-/-

+/+/-/+
-/+

+/+
+/+
+/+
+/+

1

Percent wieght remaining

0.95

0.9

0.85

0.8

0.75
2

4

6

Days of Degradation

8

Figure 2: Degradation profile of chitosan sponge/microbead composite. Error bars
denote standard deviation.
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10

Figure 3: Direct contact cell viability results. Results are reported in luminescence
values. * denotes statistical difference (T test <0.05).

Discussion
Wound infections are becoming more difficult to treat because of increased
antibiotic resistant bacteria. Systemic delivery of antibiotics is not always effective and
often do not achieve high antibiotic concentrations [7, 9, 22, 40]. Systemic antibiotic
delivery can also have toxic side effects and can result in antibiotic resistant infections
while not being able to reach avascular areas of the body or wounds [7, 9, 21, 22, 40].
Stimuli responsive local drug delivery presents better options for treating and preventing
wound infections including delivering high levels of antibiotics to avascular areas of the
body [21]. Bacteria that are resistant to systemic antibiotic therapy are more susceptible
to higher levels of localized antibiotic delivery [21]. Another potential advantage is local
delivery offers more control over the release profile, and the antibiotic can reach the
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infection site more quickly than systemic delivery [21, 54]. This control of elution
profile is greater with stimuli responsive, local drug delivery.
This study does have several limitations. One major limitation was the limited
amount of time each sample could be exposed to the pulsed magnetic field. We were
limited to providing each sponge only 5 min of “stimulation” in-between time points.
Another limitation of this study is short investigated elution duration at 72 hours,
although 72 hours does cover typical wound debridement timing. Finally, only limited,
common representative antibiotics were evaluated. More antibiotics need to be tested to
further understand the potential of this chitosan microbead/sponge composite.
Our study designed and fabricated a chitosan sponge/microbead composite
capable of absorbing and eluting antibiotics passively with and without stimulation. As
previous studies have shown, we recorded a rapid “burst” release of antibiotic (800-1500
µg/ml) within the first few hours [2, 6, 21, 43, 52]. Compared to the chitosan sponge
used in Noel et. al, our study shows a similar release profile of both amikacin and
vancomycin [43]. Our results showed a similar burst release to that of calcium sulfate
loaded with tobramycin [52]. However, calcium sulfate loaded with tobramycin shows a
more prolonged release (28 days) of antibiotics than our chitosan sponge/microbead
composite (3 days) [52]. This chitosan sponge/microbead composite does have
similarities to the collagen sponge system because both are biodegradable and
biocompatible [14]. Our composite is capable of being pre-loaded with antibiotics or
having the antibiotics being loaded at the point of care and controlling the release through
stimuli where the collagen sponge was only preloaded with antibiotics [14]. The collagen
sponge system has a higher burst release (3800 µg/ml) at hour 1 than our composite, but
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has significantly less release at 24 hours (6.9 µg/ml), approximately 25 times less than
our composite [14].
The activity levels of the antibiotics released from our chitosan sponge/microbead
composite were similar to previous results with the chitosan sponge [43]. Our activity
results show that our sponge/microbead composites can elute active levels of amikacin or
vancomycin for 48 hours. The addition of the chitosan microspheres does not change the
release of active antibiotic when compared to previous chitosan sponge studies [46, 47,
58]. Noel et. al was able to elute active levels of vancomycin for 72 hours against a
different strain of S. aureus (Cowan 1 MIC between 0.5 µg/ml and 1.0 µg/ml) while our
activity was only for 48 hours against S. aureus (UAMS 1 MIC 1.56-3.125 µg/ml) [43].
This difference in antibiotic susceptibility may account for the decrease in active
antibiotics from our composite compared to Noel‟s chitosan sponge [43].
The need for more control of local antibiotic delivery to improve clinical
outcomes was a motivation for this study. Our preliminary data suggests that our
sponge/microbead composite can release inhibitory concentration of antibiotic as well as
provide additional control over the release profile with outside stimuli at 3, 6, and 72
hours. We did test ultrasound as a stimulus and it gave more control over the release
profile than pulsed magnetic field. However, because ultrasound is not clinically
relevant, it was not included in this study. This composite demonstrates the ability to be
point of care loaded with antibiotics, giving physicians more antibiotic, or other active
agent, options for treatment. With further investigations including expanded in-vitro and
in-vivo evaluation, as well as assessment against more stimuli such as pulsed electric
field or ultrasound, this composite may be able to provide better clinical outcomes and
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more control over the antibiotic release pattern as adjunct therapy in traumatic wounds
and potentially provide prophylactic use in other surgical sites.
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CHAPTER 3: CONCLUSION
In this preliminary in vitro study, novel chitosan microbead/sponge composites
were made for pre-loading or point of care loading of antibiotics/proteins for treatment or
prevention of musculoskeletal infections. All of these composites show steady
degradation of approximately 10% total initial weight by 10 days. Pre-loading
composites with amikacin seems to increase the sustained release of amikacin from the
composite compared to a chitosan sponge alone. However, when a continuous sonication
stimulus is applied to the amikacin pre-loaded composites, a higher burst release of
amikacin (3000 µg/ml) is seen followed by less of a sustained release of amikacin when
compared to non-stimulated, amikacin pre-loaded composites. These composites, when
pre-loaded with amikacin, elute inhibitory concentrations of amikacin against
Pseudomonas aruginosa (PA) but only for 24 hours, regardless of stimulus.
Pre-loading microbeads with ALP and the composite with vancomycin releases
bacterial inhibitory concentrations of vancomycin against S. aureus for 48 hours.
However, when sonication is applied, the composite releases bacterial inhibitory
vancomycin levels for 24 hours only. This reduction by 24 hours of bacterial inhibition
suggests a much faster release of vancomycin due to sonication. Sonication also caused
an increased initial release of active ALP with a slight decrease in sustained release.
These increases in burst release with less sustained release coincide with the pre-loading
amikacin results.
The results from pre-loading the microbeads and point of care loading the
composite combined with a magnetic pulse stimulus show interesting results. The
composites elute bacterial inhibitory levels of vancomycin and amikacin against S. aureus
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and PA respectively through 48 hours with and without stimulus (magnetic pulse). This
inhibition of PA for 48 hours is an improvement of 24 hours from the amikacin preloading study. This suggests that the extra lyophilization procedure involved in preloading the composite reduces the activity of pre-loaded amikacin. The magnetic pulse
stimulus seems to increase the sustained elution of vancomycin levels, while decreasing
the sustained amikacin release levels.
The preliminary in vitro data from this study demonstrated that the incorporation
of genipin cross-linked, antibiotic loaded chitosan microspheres into a chitosan sponge
creates a tailorable and controllable drug delivery composite that may show promise for
in vivo studies and potential translation to clinical evaluations with additional
refinements. The ability of the physician to select a specific antibiotic to load into the
composite and control its release with a stimulus based on patients needs could result in
more efficacious and faster treatment of infections and a possible reduction in antibiotic
resistance development in the patient. While further in vivo and in vitro studies are
needed to assess the true effectiveness of these stimuli responsive microbead/sponge
composites, this preliminary study has demonstrated that chitosan microbead/sponge
composites may be capable of being stimuli responsive and providing sustained local
antibiotic therapy.
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CHAPTER 4: FUTURE WORK

In order to fully evaluate the properties of this chitosan microbead/sponge
composite, additional in vitro materials characterization tests are needed. These tests
include more extended degradation studies beyond 10 days including degradation in
response to stimuli, more differentiation between the differences in pre-loaded versus
point of care antibiotic loaded composites with the same stimulus and antibiotic, more
elution tests on other stimuli such as pulsed electric fields, and more stimuli tests on
additional antibiotics or other drugs, specifically bone related proteins. An extended in
vivo degradation study with various stimuli would provide a more complete degradation
profile of the composite and local tissue response. A proof of principle infected mouse
catheter animal model with various stimuli applied would demonstrate the functional
efficacy of the composites as local and stimuli responsive antibiotic delivery system for
preventing and treating infections.
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APPENDIX: ULTRASOUND AS STIMULUS TO RELEASE AMIKACIN,
VANCOMYCIN OR ALKALINE PHOSPHATASE (ALP)

Introduction
Ultrasound or sonication has been shown to be a stimulus option for the chitosan
sponge/microbead composite. Also, a representative bone growth protein, alkaline
phosphatase (ALP), was used to assess the release of protein from the composite.
Therefore, composites loaded with amikacin and composites loaded with vancomycin
and ALP were tested for elution in response to sonication as well as antibiotic activity
against PA and S. aureus.
Materials and Methods
The Fe3O4 nanoparticles were made following the methods of Hu et. al [20].
1.35g of FeCl3·6H2O was dissolved in 40 ml of ethylene glycol to form a clear solution.
Then 1.0g of polyethylene glycol 20000 and 3.6g of NaAc·3H2O were added to the
solution. Once the reactants were fully dissolved, the solution was transferred into a
Teflon-lined autoclave vessel with a capacity of 50ml, and heated at 200oC for 8 hours.
After the autoclave, the products were collected, rinsed with de-ionized water and ethanol
several times, then dried in a vacuum oven at 60oC for 6 hours.
Chitosan is obtained from Chitinor AS (Norway). For the purposes of this
experiment, the DDA (83%) and molecular weight (250550 Da) were not intentionally
changed. Chitosan microspheres containing Fe3O4 nanoparticles were made following the
procedures in Jain et. al[57]. A 4% w/v solution of chitosan, 5% w/v aqueous acetic acid,
2% w/v Fe3O4 nanoparticles, 5mg/ml amikacin or representative protein (alkaline
phosphates ALP [59] from MP Biomedicals) was prepared. This solution is dispersed in
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a 1:1 mixture of light and heavy mineral oil (paraffin oil from Fisher Chemical)
containing .013 w/v Span 80 surfactant (Sigma Life Science). This oil solution was
allowed to mix for approximately 15 minutes. Next, genipin (Wako) was added to make
the solution 5mM of genipin. The solution was then stirred overnight (approximately 20
hours) allowing the genipin to crosslink the chitosan. After crosslinking, the solution was
rinsed with solutions of hexanes, methanol, and acetone, separately in this sequence to
remove the mineral oil, and then allowed to air dry in laboratory chemical fume hood.
Chitosan sponges were made following the procedure in Noel et. al[43]. 10.0
grams of Chitofarm S (83% DDA, 250550 Da) chitosan was dissolved in 1% v/v blended
acid solvent (75/25 lactic to acetic acid). This solution was allowed to stir for between 14 hours or until the chitosan was dissolved. Then 35ml of the chitosan solution was
pipetted into small aluminum weigh dishes. These dishes were frozen at -80oC (Thermo
Scientific Forma 900 Series -80oC freezer) for at least one hour, then placed into a freeze
dryer (Labconco Freezone 2.5) and lyophilized for 48 hours. The chitosan solution in the
dishes formed sponge-like components during the lyophilization. These sponges were
neutralized in 0.6 M NaOH for 30-40 seconds, and then rinsed with distilled water until a
the rinsing solution read neutral (pH of 7) on a pH strip. The sponges were again frozen
at -80oC and lyophilized a second time for 48 hours. The chitosan microspheres
containing amikacin and Fe3O4 nanoparticles were hydrated into the sponges after the
second lyophilization with either distilled water or a solution of 5mg/ml antibiotic. Preloaded composites were lyophilized a 3rd time.
Two separate elution tests were performed, one involving the release of just
amikacin (Table 1); another involving the release of vancomycin and alkaline
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phosphatase, ALP, (Table 2). The groups tested are represented in Tables 1-2. Each
elution was performed in 20 ml of PBS. Three 1 ml samples were taken from each
sponge (n=3) at every time point: 1, 3, 6, 24, 48, and 72 hours. At each time point, PBS
was completely refreshed. Samples were frozen until they were analyzed. For sonication
or ultrasound testing, a standard laboratory ultrasonic cleaner (Fisher Scientific FS60H,
100W, 42kHz) was used. Ultrasound was used as a basic laboratory experiment to show
stimuli responsiveness. The amikacin levels were measures using an Abbott TDx FLx
Immunology Analyzer. Vancomycin levels were measured using a protein assay (Pierce
BCA Protein Assay Kit) or high pressure liquid chromatography (HPLC). ALP levels
were measured using an ALP assay. Statistical analysis of the concentrations was
performed using SigmaPlot.

Table 1: Elution groups for amikacin (Am) release due to sonication (Son).
Sponge
Sponge
Sonication
Sonication stimulus
Composite Loaded with
Loaded with
stimulus applied
applied after 24
Group
5mg/ml
beads loaded
constantly
hour time point
amikacin
with amikacin
Am Son 1
Yes
No
No
No
Am Son 2
Yes
Yes
No
No
Am Son 3
Yes
Yes
Yes
Yes
Am Son 4
Yes
Yes
No
Yes
Am Son 5
No
Yes
No
No
Am Son 6
No
Yes
Yes
Yes

Table 2: Elution groups for vancomycin (Vn) and ALP release due to sonication (Son).
Sponge loaded
Sponge
with
Composite loaded with
Sonicated
microbeads
Group
vancomycin
constantly
loaded with
(Vn)
ALP
Vn Son 1
Yes
Yes
Yes
Vn Son 2
Yes
Yes
No
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The biological activity of the sponge eluates were analyzed using turbidity assays.
Samples were tested to determine if antibiotic is still active against P. aeruginosa (PA
ATCC 27317, minimum inhibitory concentration (MIC) 6.25-12.5 µg/ml amikacin) or S.
aureus (UAMS 1 MIC 1.56-3.125 µg/ml vancomycin) depending on whether amikacin or
vancomycin were eluted, respectfully [43]. Tubes were prepared with trypticase soy
broth (TSB) and inoculated with respected bacteria [43]. Positive and negative controls
were used. The sample eluates were added to the tubes, resulting in a 10x dilution, and
incubated at 37oC for 24 hours [43]. After incubation, the samples were shaken and read
with a spectrophotometer at 530 nm [43].
Results
We attempted to fabricate an adaptable, cytocompatible and biodegradable
chitosan sponge/microbead composite capable of absorbing antibiotics and eluting them
in response to either ultrasound or pulsed magnetic field as an adjunct therapy to
debridement and lavage. The sponge/microbead composite initially has a burst release
(at 1 hour) followed by a sustained release (through 72 hours) of antibiotics without
stimulation. The elution profile of pre-loaded amikacin composites in response to
sonication is given in Figures 1a and 1b. The non-stimulated composite had
approximately twice the sustained release level of amikacin (22 µg/ml) compared to the
control chitosan sponge. If stimulated by ultrasound, the composite has a higher burst
release of amikacin, approximately 1.5 times (3020 µg/ml), than the control chitosan
sponge and non-stimulated composite. However, when the stimulus is constantly applied
for 72 hours, the sustained amikacin release of the stimulated composite is reduced to
approximately 86% of the sustained release of the non-stimulated composite. The
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addition of the microbeads to form the composite does lead to a higher sustained elution
of amikacin, approximately 2 times (22 µg/ml), versus the control sponge at 72 hours.
The elution profile of the pre-loaded vancomycin and alkaline phosphatase (ALP)
composites with sonication stimulus is shown in Figure 2a and Figure 2b. Ultrasound
stimulation increases the burst release of ALP (149.8 ng/ml) while decreasing the
sustained release of vancomycin when compared to non-stimulated composites at hour 48
by 57%.
The activity results for the pre-loaded amikacin sonication elution are presented in
Table 3. The sponges release inhibitory levels of amikacin against PA for 24 hours. The
pre-loaded vancomycin/ALP ultrasound elution activity results are presented in Table 4.
The sonicated composites released inhibitory levels of vancomycin against S. aureus for
24 hours whereas the non-sonicated composites released inhibitory levels of vancomycin
against S. aureus for 48 hours.

Figure 1a: Amikacin elution profile with sonication stimulus. Groups are noted in Table
1. * denotes significant difference (Holms-Sidak <0.05) from control sponge (Am Son
1). Error bars denote standard deviation. Group Am Son 2 is non-stimulated composite.
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Figure 1b: Amikacin elution profile with sonication stimulus. Groups are noted in Table
1. * denotes significant difference (T-test <0.05) from non-stimulated composite (Am
Son 5). Error bars denote standard deviation. Amikacin was only pre-loaded in
microbead part of composite so the levels released were much lower.

Table 3: Activity for amikacin elution with sonication stimulus against PA ATCC 27317.
Groups are denoted in Table 1. + denotes bacterial growth. – denotes inhibition of
growth.
Composite
1 hr
3 hr
6 hr
24 hr
48 hr
72 hr
Group
Am Son 1
+
+
Am Son 2
+
+
Am Son 3
+
+
Am Son 4
+
+
Am Son 5
+
+
+
+
+
+
Am Son 6
+
+
+
+
+
+
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Figure 2a: Active alkaline phosphatase (ALP) 72 hour elution profile with sonication
stimulus. * denotes significant difference (T-test <0.05) from non-sonicated composite
(Vn Son 2). Error bars denote standard deviation.

Figure 2b: Vancomycin 72 hour elution profile with sonication stimulus. * denotes
significant difference (T-test <0.05) from non sonicated composite (Vn Son 2). Error
bars denote standard deviation.
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Table 4: Activity results for vancomycin ALP sonication elution versus UAMS 1 Staph.
Groups are denoted in Table 2. + denotes bacterial growth. – denotes inhibition of
growth.
Composite
1 hr
3 hr
6 hr
24 hr
48 hr
72 hr
Group
Vn Son 1
+
+
Vn Son 2
+

Discussion
Our study designed and fabricated a chitosan sponge/microbead composite
capable of absorbing and eluting antibiotics passively with and without stimulation. As
previous studies have shown, we recorded a rapid “burst” release of antibiotic (800-3000
µg/ml) within the first few hours [2, 6, 21, 43, 52]. Compared to the chitosan sponge
used in Noel et. al, our study shows a similar release profile of both amikacin and
vancomycin with only slight differences. This composite showed 1) increased burst
release of amikacin in response to sonication, 2) decreased sustained release of
vancomycin in response to sonication, and 3) increased sustained release of amikacin,
approximately two fold, with the addition of chitosan microbeads containing antibiotic
and iron-oxide nanoparticles to the chitosan sponge [43]. Our results showed a similar
burst release to that of calcium sulfate loaded with tobramycin [52]. However, calcium
sulfate loaded with antibiotics shows a more prolonged release (28 days) of antibiotics
than our chitosan sponge/microbead composite (3 days) [52]. This chitosan
sponge/microbead composite does have similarities to the collagen sponge system
because both are biodegradable and biocompatible [14]. Our composite is capable of
being pre-loaded with antibiotics or having the antibiotics being loaded at the point of
care and controlling the release through stimuli where the collagen sponge was only
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preloaded with antibiotics [14]. The collagen sponge system has a higher burst release
(3800 µg/ml) at hour 1 than our composite, but has significantly less release at 24 hours
(6.9 µg/ml), approximately 25 times less than our composite [14].
The activity levels of the antibiotics released from our chitosan sponge/microbead
composite were similar to previous results with the chitosan sponge [43]. Our activity
results show that our sponge/microbead composites can elute active levels of amikacin or
vancomycin for 48 hours. Sonication shortens the release of active vancomycin to 24
hours and the addition of the chitosan microspheres does not change the release of active
antibiotic when compared to previous chitosan sponge studies [46, 47, 58]. Noel et. al
was able to elute active levels of vancomycin for 72 hours against a different strain of S.
aureus (Cowan 1 MIC between 0.5 µg/ml and 1.0 µg/ml) while our activity was for
UAMS 1 S. aureus (MIC 1.56-3.125 µg/ml) [43]. This difference in antibiotic
susceptibility may account for the decrease in active antibiotics from our composite
compared to Noel‟s chitosan sponge [43].
The need for more control of local antibiotic delivery to improve clinical
outcomes was a motivation for this study. Our preliminary data suggests that our
sponge/microbead composite can release inhibitory concentration of antibiotic as well as
provide additional control over the release profile with two outside stimuli. This
composite demonstrates the ability to be preloaded or point of care loaded with
antibiotics, giving physicians more antibiotic or other active agent options for treatment.
With further investigations including expanded in-vitro and in-vivo evaluation, this
composite may be able to provide better clinical outcomes and more control over the
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antibiotic release pattern as adjunct therapy in traumatic wounds and potentially provide
prophylactic use in other surgical sites.
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